Patients News | pharmaphorum

News

Huma CEO Dan Vahdat speaking at World Economic Forum in Davos, 2023

Class II approval revs up Huma’s SaMD platform

Huma Therapeutics has been granted Class II clearance from the FDA for its Software-as-a-Medical-Device (SaMD) disease management platform, dramatically expanding the rang

News

Akili launches OTC version of digital therapeutic for ADHD

Digital health company Akili has launched a non-prescription version of its attention-deficit hyperactivity disorder (ADHD) digital therapeutic EndeavorRx, that can be dow

News

UK plans $40m pilot of obesity drug Wegovy in primary care

Novo Nordisk’s obesity drug isn’t even available in the UK yet, but the government has already launched a pilot programme that could see access to the drug expanded throug

News

ASCO: Grail’s cancer blood test ‘promising’ in UK trial

Researchers in the UK say Grail’s blood test for more than 50 different types of cancer has shown promise in a trial involving thousands of people with suspected cancer sy

News

Vydura is NHS’ first oral CGRP for migraine prevention

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this ye

News

Parkinson’s wearable matches experts in clinical trial

A new clinical study has found that a wearable device developed by PD Neurotechnology was 95% accurate in detecting and assessing motor symptoms of Parkinson’s disease, wh

Class II approval revs up Huma’s SaMD platform

Akili launches OTC version of digital therapeutic for ADHD

UK plans $40m pilot of obesity drug Wegovy in primary care

ASCO: Grail’s cancer blood test ‘promising’ in UK trial

Vydura is NHS’ first oral CGRP for migraine prevention

Parkinson’s wearable matches experts in clinical trial

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks